litlas
Log inCreate account

Timothy A. Yap

Active 2007–2025

177
Papers
25,122
Citations
78
h-index
160
i10-index

Citations

Citations per year for Timothy A. Yap1896: 1 citations1995: 1 citations1999: 1 citations2007: 2 citations2008: 30 citations2009: 84 citations2010: 230 citations2011: 270 citations2012: 279 citations2013: 268 citations2014: 284 citations2015: 235 citations2016: 275 citations2017: 224 citations2018: 208 citations2019: 834 citations2020: 1,011 citations2021: 1,142 citations2022: 1,063 citations2023: 946 citations2024: 1,526 citations2025: 892 citations2026: 28 citations1897–1994: no citations, so these years are not shown1996–1998: no citations, so these years are not shown2000–2006: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,431 citing papers, 25.8% of this breakdownChina: 1,875 citing papers, 14.1% of this breakdownUnited Kingdom: 1,168 citing papers, 8.8% of this breakdownItaly: 670 citing papers, 5% of this breakdownGermany: 540 citing papers, 4.1% of this breakdownFrance: 481 citing papers, 3.6% of this breakdownCanada: 474 citing papers, 3.6% of this breakdownSpain: 419 citing papers, 3.1% of this breakdownAustralia: 326 citing papers, 2.5% of this breakdownNetherlands: 322 citing papers, 2.4% of this breakdownJapan: 295 citing papers, 2.2% of this breakdownSwitzerland: 284 citing papers, 2.1% of this breakdown
0%25.8%Other 22.7%

Institutions

Fields

  • Medicine50.4%
  • Biochemistry, Genetics and Molecular Biology39.9%
  • Immunology and Microbiology3.9%
  • Computer Science1%
  • Engineering0.8%
  • Materials Science0.8%
  • Other3.2%

Topics

  • PARP inhibition in cancer therapy7.5%
  • DNA Repair Mechanisms5.4%
  • Cancer Genomics and Diagnostics3.6%
  • Cancer Immunotherapy and Biomarkers2.8%
  • PI3K/AKT/mTOR signaling in cancer2.6%
  • Prostate Cancer Treatment and Research2%
  • Other76.1%

Coauthors

All papers

Open in search
  1. State-of-the-art strategies for targeting the DNA damage response in cancer

    Authors: Patrick G. Pilié, Chad Tang, Gordon B. Mills, Timothy A. Yap - Nature Reviews Clinical Oncology 2018 cited by 1,197

  2. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

    Authors: Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam, Hagop M. Kantarjian, Farhad Ravandi, Meghan Collins, Maria Emilia Di Francesco, Ecaterina E. Dumbrava, Siqing Fu, Sisi Gao, Jason Gay, Sonal Gera, Jing Han, David S. Hong, Elias Jabbour, Zhenlin Ju, Daniel D. Karp, Alessia Lodi, Jennifer R. Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A. Piha‐Paul, Jordi Rodón, Carolina Salguero, Koji Sasaki, Anand Kumar Singh, Vivek Subbiah, Apostolia M. Tsimberidou, Quanyun A. Xu, Musa Yılmaz, Qi Zhang, Yuan Li, Christopher A. Bristow, Meenakshi B. Bhattacharjee, Stefano Tiziani, Timothy P. Heffernan, Christopher P. Vellano, Philip Jones, Cobi J. Heijnen, Annemieke Kavelaars, Joseph R. Marszalek, Marina Konopleva - Nature Medicine 2023 cited by 377

  3. Development of Immunotherapy Combination Strategies in Cancer

    Authors: Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, Justin T. Moyers, Michael A. Curran, Hussein A. Tawbi - Cancer Discovery 2021 cited by 320

  4. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Authors: Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono - New England Journal of Medicine 2009 cited by 3,632

  5. Targeting the PI3K pathway in cancer: are we making headway?

    Authors: Filip Jankú, Timothy A. Yap, Funda Meric‐Bernstam - Nature Reviews Clinical Oncology 2018 cited by 1,032

  6. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

    Authors: Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A. Yap, Gordon B. Mills, Guang Peng - Cancer Research 2018 cited by 592

  7. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study

    Authors: Alexis Tabah, Niccolò Buetti, Quentin Staiquly, Stéphane Ruckly, Murat Akova, Abdullah Tarık Aslan, Marc Léone, Andrew Conway Morris, Matteo Bassetti, Kostoula Arvaniti, Jeffrey Lipman, Ricard Ferrer, Haibo Qiu, José-Artur Paiva, Pedro Póvoa, Liesbet De Bus, Jan J. De Waele, Farid Zand, Mohan Gurjar, Adel Alsisi, Khalid Abidi, Hendrik Bracht, Yoshiro Hayashi, Kyeongman Jeon, Muhammed Elhadi, François Barbier, Jean‐François Timsit, on behalf of the EUROBACT-2 Study Group, ESICM, ESCMID ESGCIP and the OUTCOMEREA Network, Alexis Tabah, Hamish Pollock, Ben Margetts, Meredith Young, Neeraj Bhadange, Steven Tyler, Anne Ledtischke, Mackenzie Finnis, Anne Ledtischke, Mackenzie Finnis, Jyotsna Dwivedi, Manoj Saxena, Vishwanath Biradar, Natalie Soar, Vineet Sarode, David Brewster, Adrian Regli, Elizabeth Weeda, Samiul Parvez Ahmed, Cheryl Fourie, Kevin B. Laupland, Mahesh Ramanan, James Walsham, Jason Meyer, Edward Litton, Anna Maria Palermo, Timothy A. Yap, Ege Eroglu, Antony Attokaran, C’havala Jaramillo, Khalid Mahmood Khan Nafees, Nurhikmahtul Aqilah Haji Abd Rashid, Haji Adi Muhamad Ibnu Walid, Tomas Mon, P. Dhakshina Moorthi, Shah Sudhirchandra, Dhadappa Damodar Sridharan, Qiu Haibo, Jianfeng Xie, Lu Wei-Hua, Zhen Wang, Chuanyun Qian, Jili Luo, Xiaomei Chen, Hao Wang, Peng Zhao, Juan Zhao, Qiu Wusi, Chen Mingmin, Lei Xu, Chengfen Yin, Ruilan Wang, Jinfeng Wang, Yongjie Yin, Min Zhang, Jilu Ye, Chungfang Hu, Suming Zhou, Min Huang, Jing Yan, Yan Wang, Bingyu Qin, Ling Ye, Xie Weifeng, Li Peije, Nan Geng, Yoshiro Hayashi, Toshiyuki Karumai, Masaki Yamasaki, Satoru Hashimoto, Koji Hosokawa, Junichiro Makino and 615 more - Intensive Care Medicine 2023 cited by 246

  8. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

    Authors: Timothy A. Yap, David S.P. Tan, Angelika Terbuch, Reece Caldwell, Christina Guo, Boon Cher Goh, Valerie Heong, Noor R. Md. Haris, Saira Bashir, Yvette Drew, David S. Hong, Funda Meric‐Bernstam, Gary Wilkinson, Joseph Hreiki, Antje M. Wengner, Friedhelm Bladt, Andreas Schlicker, Matthias Ludwig, Yinghui Zhou, Li Liu, Sonal Bordia, Ruth Plummer, Eleni Lagkadinou, Johann S. de Bono - Cancer Discovery 2020 cited by 256

  9. PARP inhibitors: enhancing efficacy through rational combinations

    Authors: Deepak Bhamidipati, Jaime Haro-Silerio, Timothy A. Yap, Natalie Y.L. Ngoi - British Journal of Cancer 2023 cited by 153

  10. Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance

    Authors: Stephen J. Pettitt, Jessica Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy A. Yap, Syed Haider, Andrew Tutt, Christopher J. Lord - Cancer Discovery 2020 cited by 184

  11. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

    Authors: Timothy A. Yap, Elisa Fontana, Elizabeth K. Lee, David R. Spigel, Martin Højgaard, Stéphanie Lheureux, Niharika B. Mettu, Benedito A. Carneiro, Louise Carter, Ruth Plummer, Gregory M. Coté, Funda Meric‐Bernstam, Joseph O’Connell, Joseph D. Schonhoft, Marisa J. Wainszelbaum, Adrian J. Fretland, Peter Manley, Yi Xu, Danielle Ulanet, Victoria Rimkunas, Mike Zinda, María Koehler, Ian M. Silverman, Jorge S. Reis‐Filho, Ezra Y. Rosen - Nature Medicine 2023 cited by 102

  12. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

    Authors: Jessica Brown, Brent O’Carrigan, Stephen P. Jackson, Timothy A. Yap - Cancer Discovery 2016 cited by 629

  13. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

    Authors: Timothy A. Yap, Brent O’Carrigan, Marina S. Penney, Joline S.J. Lim, Jessica Brown, Maria J. de Miguel, Nina Tunariu, Raquel Pérez-López, Daniel Nava Rodrigues, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Brian Hare, K. Mcdermott, Saira Khalique, Chris T. Williamson, Rachael Natrajan, Stephen J. Pettitt, Christopher J. Lord, Udai Banerji, John R. Pollard, Juanita Lopez, Johann S. de Bono - Journal of Clinical Oncology 2020 cited by 248

  14. Antibody-drug conjugates in lung cancer: dawn of a new era?

    Authors: Niamh Coleman, Timothy A. Yap, John V. Heymach, Funda Meric‐Bernstam, Xiuning Le - npj Precision Oncology 2023 cited by 119

  15. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

    Authors: Chaoyang Sun, Jun Yin, Yong Fang, Jian Chen, Kang Jin Jeong, Xiaohua Chen, Christopher P. Vellano, Zhenlin Ju, Wei Zhao, Dong Zhang, Yiling Lu, Funda Meric‐Bernstam, Timothy A. Yap, Maureen M. Hattersley, Mark J. O’Connor, Huawei Chen, Stephen E. Fawell, Shiaw‐Yih Lin, Guang Peng, Gordon B. Mills - Cancer Cell 2018 cited by 302

  16. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors

    Authors: Timothy A. Yap, Aditya Bardia, Michael Dvorkin, Matthew D. Galsky, J. Thaddeus Beck, David R. Wise, O. B. Karyakin, Gábor Rubovszky, Nikolay Kislov, Kristoffer Staal Rohrberg, Anil A. Joy, Melinda L. Telli, Alison M. Schram, Umberto Conte, Colombe Chappey, Ross Stewart, Daria Stypinski, Elisabete Michelon, Rossano Cesari, Panagiotis A. Konstantinopoulos - JAMA Oncology 2022 cited by 100

  17. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

    Authors: Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, Mark J. O’Connor, Timothy A. Yap - Clinical Cancer Research 2019 cited by 332

  18. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

    Authors: Yong Fang, Daniel J. McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P. Vellano, Yiling Lu, Yongsheng Li, Kang Jin Jeong, Zhiyong Ding, Jiyong Liang, Steven W. Wang, Hui Dai, Sanghoon Lee, Nidhi Sahni, Imelda Mercado‐Uribe, Tae-Beom Kim, Ken Chen, Shiaw‐Yih Lin, Guang Peng, Shannon N. Westin, Jinsong Liu, Mark J. O’Connor, Timothy A. Yap, Gordon B. Mills - Cancer Cell 2019 cited by 241

  19. ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer

    Authors: Zhe Tang, Patrick G. Pilié, Chuandong Geng, Ganiraju C. Manyam, Guang Yang, Sanghee Park, Daoqi Wang, Shan Peng, Cheng Wu, Guang Peng, Timothy A. Yap, Paul G. Corn, Bradley M. Broom, Timothy C. Thompson - Clinical Cancer Research 2021 cited by 142

  20. First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

    Authors: Timothy A. Yap, Maria Vieito, Capucine Baldini, Juan Manuel Sepúlveda-Sánchez, Shunsuke Kondo, Matteo Simonelli, Rasha Cosman, Andre van der Westhuizen, Victoria Atkinson, Antoine F. Carpentier, Mario Löhr, Rebecca Redman, Warren Mason, Andres Cervantes, Emilie Le Rhun, Sebastian Ochsenreither, Louise Warren, Yumin Zhao, Sophie Callies, Shawn T. Estrem, Michael Man, Leena Gandhi, Emin Avsar, Davide Melisi - Clinical Cancer Research 2021 cited by 74

  21. Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Authors: Peter C.C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui‐Roelvink, Charlie Gourley, Jacques De Grève, Jan Lubiński, Susan Shanley, Christina Messiou, Roger A’Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye - Journal of Clinical Oncology 2010 cited by 992

  22. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

    Authors: Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, Adam W. Cook, Christina E. Wong, Ronald J. Hinklin, Yutong Jiang, Eric N. Brown, Nickolas A. Neitzel, Ellen R. Laird, Wen‐I Wu, Anurag Singh, Ping Wei, Keith A. Ching, John J. Gaudino, Patrice A. Lee, Dylan P. Hartley, S. Michael Rothenberg - Cancer Discovery 2023 cited by 68

  23. Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations

    Authors: Timothy A. Yap, David J. Kwiatkowski, Jayesh Desai, Ibiayi Dagogo‐Jack, Michael Millward, Hedy L. Kindler, Anthony W. Tolcher, Sophia Frentzas, Archie Thurston, Len Post, F Andrew Dorr - Cancer Research 2023 cited by 64

  24. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer

    Authors: Kurt W. Evans, Erkan Yuca, Stephen M. Scott, Ming Zhao, Natalia Paez Arango, Christian X. Cruz Pico, Turçin Saridogan, Maryam Shariati, Caleb A. Class, Christopher A. Bristow, Christopher P. Vellano, Xiaofeng Zheng, Ana M. González-Angulo, Xiaoping Su, Coya Tapia, Ken Chen, Argun Akçakanat, Bora Lim, Debu Tripathy, Timothy A. Yap, Maria Emilia Di Francesco, Giulio Draetta, Philip Jones, Timothy P. Heffernan, Joseph R. Marszalek, Funda Meric‐Bernstam - Cancer Research 2021 cited by 157